Additional studies using TMPRSS2-ERG models will aid in defining basic mechanisms of action and of synergism with defined mutations, as well as helping to establish accurate preclinical models for prostate cancer treatment. This evidence concerns the gene TMPRSS2 and prostate carcinoma.